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Abstract
Introduction: To investigate whether baseline levels of anti-citrullinated protein antibody (ACPA) or IgM rheumatoid 
factor (IgM-RF) and changes in the year thereafter are associated with disease activity, functional and radiographic 
outcome in early arthritis patients, and provide additional information over baseline autoantibody status.
Methods: In 545 early arthritis patients ACPA and IgM-RF levels, disease activity (DAS28), the Health Assessment 
Questionnaire (HAQ) and Sharp/Van der Heijde Score (SHS) were assessed annually. Baseline status, levels and first-year 
changes of the autoantibodies were associated with these measures at the two-year follow-up and sub-analysed 
according to autoantibody status.
Results: The mean age was 52.7 years, 69% was female, at baseline 56% was ACPA positive, 47% IgM-RF positive. At the 
two-year follow-up the mean DAS28 was 2.88, and the median HAQ and SHS were 0.38 and 1, respectively. At one year, 
ACPA and IgM-RF levels had decreased by 31% and 56%, respectively. A switch from negative to positive occurred in 
2% for ACPA and 3% for IgM-RF. Positive ACPA and RF status were both associated with SHS at two years (P < 0.001), but 
baseline levels only showed a minor correlation of ACPA with DAS28 and HAQ at two years. Level changes were not 
associated with the outcome parameters.
Conclusions: Baseline levels and first-year changes of ACPA and IgM-RF are hardly associated with outcome after two 
years. Seroconversion seldom occurs. Therefore, it does not appear useful to repeat ACPA or IgM-RF measurements.
Introduction
Rheumatoid arthritis (RA) is often accompanied by auto-
immune phenomena, notably anti-citrullinated protein
antibodies (ACPA) and rheumatoid factor (RF). Although
ACPA-positive RA cannot be distinguished from ACPA-
negative RA at first presentation [1,2], several studies
have demonstrated that the presence of ACP A is prog-
nostic for disease severity, radiographic erosions, as well
as t he deve lopmen t of RA in synovitis of recen t onset
[1,3-8]. Recently, higher ACPA levels have been found in
patients who developed RA compared with those who did
not develop RA [9]. Most studies assessed the predictive
value of the presence of ACPA [3,8,10-15]. However, it is
a s  y e t  u n c l e a r  w h e t h e r  h i g h  l e v e l s  o f  A C P A  p r e d i c t
poorer outcome [16-20]. In a prospective study of 104
early RA patients, higher baseline ACPA levels were asso-
ciated with erosive disease after two years [20]. Another
study of 99 early RA patients reported a small, almost sig-
nificant correlation between baseline serum ACPA levels
and radiographic progression after five years [18]. A third
study of 238 early RA patients found a higher radio-
graphic progression rate after 10 years of high-positive
ACPA versus low-positive ACPA patient groups [19].
Two studies assessed levels of ACPA in patients with
longstanding RA. One of these reported a weak associa-
tion (in 180 patients) between ACPA levels and radio-
graphic progression rate [16]. The other was a cross-
sectional study of 241 RA patients with a mean disease
duration of 8.6 years, in which mean ACPA levels were
similar in patients with or without erosions [17].
RF, mostly measured as immunoglobulin (Ig)M-RF, is
still widely used as a serological marker for the diagnosis
of RA, although it is also frequently observed in other
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inflammatory diseases [21] and in healthy elderly persons
[22] suggesting that RF can be a consequence of nonspe-
cific immune activation. Its presence is a prognostic
marker of disease activity and erosive disease [10,20].
Higher IgM-RF levels have been associated with a higher
risk for the development of RA[23]. IgM-RF levels also
seem to be associated with future radiographic damage:
in three studies, in which 78 to 149 early RA patients par-
ticipated, a correlation was found between baseline IgM-
RF levels and radiographic damage after two to three
years [20,24,25].
Reports of ACPA or IgM-RF levels and outcome in
early arthritis are therefore still few and to our knowledge
no data are a vailable on changes in levels of ACP A or
IgM-RF as a predictor of disease outcome. Changes in
autoantibody levels could possibly serve as markers of
response to therapy and thus be related to outcome.
Therefore, we investigated whether baseline status or lev-
els of ACPA or IgM-RF and their changes in the year
thereafter are associated with disease activity, functional
and radiographic outcome in a large group of early arthri-
tis patients, and whether analysis of levels provides addi-
tional information over baseline antibody status.
Materials and methods
The early arthritis cohort at the Jan van Breemen Insti-
tute, a large rheumatology clinic in Amsterdam, has been
described previously [26]. The cohort consists of patients
aged older than 18 years with peripheral arthritis of two
or more joints and a symptom duration of less than three
years, who were referred from 1995 onwards. Patients
who were previously treated with a disease modifying
anti-rheumatic drug (DMARD) and those with spondy-
larthropathy, reactive arthritis, crystal-induced arthropa-
thy, systemic lupus erythematosus, Sjögren's syndrome,
or osteoarthritis were excluded. The study was approved
by the local medical ethics committee and all patients
gave written informed consent to be included in the
study. For the present analysis, all patients with available
ACPA and IgM-RF data at baseline and after one year,
and available outcome measures at two-years follow up
were included.
Antibody measurements
ACPA levels were measured as anti-cyclic citrullinated
peptide antibodies (second generation anti-CCP ELISA,
Axis Shield, Dundee, UK). The anti-CCP test was per-
formed according to the instructions of the manufacturer
with a cut-off level for positivity set at 5 Arbitrary Units
(AU)/ml. The day to day variation (CV) was 7.4% (n = 98).
Anti-CCP levels in sera reaching 1000 AU were not fur-
ther diluted. IgM-RF was measured by in-house ELISA as
described previously [27]. The cut-off level for IgM-RF
antibody positivity is set at 30 IU determined on the basis
of receiver operator characteristics (ROC) curves
described previously [27].
Outcome measures
Disease activity was assessed with the Disease Activity
Score in 28 joints (DAS28) [28]. Functional status was
measured by the validated Dutch version of the Health
Assessment Questionnaire (HAQ) [29]. Radiographic
damage was assessed with the Sharp/Van der Heijde
Score (SHS) by one experienced rheumatologist, who was
blinded to the other variables. Two rheumatologists, with
an intraclass correlation coefficient of 0.95, each per-
formed part of the scoring.
Analysis
The baseline characteristics were age, sex, symptom
duration, percentage of patients who fulfilled the Ameri-
can College of Rheumatology (ACR) criteria for RA and
the percentage IgM-RF and ACPA positivity were com-
pared between those patients included in the study (n =
545) and those excluded (n = 1309). The change in ACPA
level was calculated as an absolute change and as a rela-
tive change compared with baseline. Outcome measures
at the two-year follow up were DAS28, HAQ and SHS, all
used as continuous variables.
Differences between groups with positive or negative
autoantibody status were tested using Mann-Whitney U
test or the chi-squared test. Correlations were deter-
mined by Pearson rho or Spearman rho as appropriate.
Partial correlations were used to correct for baseline val-
ues. For an association between change in ACPA level
and dichotomous variables, logistic regression analysis
was used. Subanalyses were performed for positive and
negative autoantibody status at baseline. All analyses
were performed using SPSS version 16.0 (SPSS Institute
Inc., Cary, NC, USA).
Results
Patient characteristics
In the study, 545 patients were included, with a mean age
of 53 years, 69% was female. Sixty-three percent fulfilled
the ACR criteria for RA at baseline or after one year. At
baseline, 56% was ACPA positive and 47% was IgM-RF
positive. At the two-year follow up the mean (standard
deviation) DAS28 was 2.88 (1.27), the median (inter-
quartile range (IQR)) HAQ was 0.38 (0 to 0.8) and the
median (IQR) SHS was 1 (0 to 6). At two years the median
(IQR) number of DMARD used was 2 (1 to 3); 27% of the
patients had used hydroxychloroquine, 39% sulphasala-
zine, 80% methotrexate and 25% prednisone, sometimes
in combination, while 2% had not used any DMARD.Ursum et al. Arthritis Research & Therapy 2010, 12:R8
http://arthritis-research.com/content/12/1/R8
Page 3 of 7
Autoantibodies: change in status and levels between 
baseline and one year
After one year, median ACPA levels had decreased signif-
icantly to 78% (P < 0.001) of the baseline levels. Higher
baseline levels were correlated with a larger absolute
change in the first year (r = -0.44, P < 0.001), but barely
with the relative change (r = -0.09, P = 0.04). The decrease
was mainly caused by ACPA-positive patients; in this
subgroup the median (IQR) ACPA level decreased signif-
icantly, equalling 69% (40 to 114%) of the baseline value
(Table 1). Of the ACPA-positive patients at baseline, 4%
became negative for ACPA after one year. In ACPA-nega-
tive patients at baseline only 2% became positive for
ACPA after one year follow up.
Median IgM-RF levels had decreased after one year to
72% (P < 0.001) of the baseline levels. Higher baseline lev-
els were associated with larger absolute as well as relative
changes (r = -0.71 and -0.54, respectively, both P < 0.001).
Also this decrease was mainly caused by IgM-RF-positive
patients; in this subgroup the median (IQR) IgM-RF level
decreased significantly, equalling 44% (27 to 71%) of the
baseline value (Table 1). Of the IgM-RF-positive patients
at baseline, 35% became negative for IgM-RF after one
year of follow up. In IgM-RF-negative patients, 3%
became positive for IgM-RF after one year of follow up.
Baseline autoantibody levels and status, and outcome
Outcome parameters at baseline
ACPA and IgM-RF levels were modestly correlated with
SHS (r = 0.12 and r = 0.11, respectively, both P = 0.01)
and not with DAS28 and HAQ (Tables 1 and 2). Patients
positive for ACPA or IgM-RF had at median more radio-
graphic damage at baseline compared with those negative
for ACPA of IgM-RF (Tables 1 and 2).
Outcome parameters at two years
Baseline ACPA and IgM-RF levels were not correlated
with DAS28 or HAQ at the two-year follow up. Levels
were only correlated with SHS (r = 0.2 and r = 0.22,
respectively, both P = 0.01). When correcting for baseline
SHS only the correlation between IgM-RF levels and SHS
remained (r = 0.14, P = 0.002).
Patients positive for ACPA or IgM-RF at baseline had at
median more radiographic damage at the two-year follow
up compared with those negative for ACPA of IgM-RF at
baseline (Tables 1 and 2). However, mean DAS28 and
median HAQ at the two-year follow up did not differ
between patients with positive or negative autoantibody
status.
In the subgroup of ACPA-positive patients, baseline
ACPA levels were modestly correlated only with DAS28
and HAQ at the two-year follow up (r = 0.15 and r = 0.13,
respectively, both P  < 0.05), while no correlation was
Table 1: The relation between ACPA status and levels and outcome variables
Correlation of 
ACPA levels at 
baseline







ACPA level at 
baseline (AU/ml), 
median (IQR)
x 89 (27-214) 1 (0-2)
ACPA level at 1 
year (AU/ml), 
median (IQR)
x 63 (22-156) 1 (0-2)
DAS28 at baseline 0.09 0.04 4.81 (1.78) 4.74 (1.36) 0.42
HAQ at baseline -0.1 0.83 0.94 (0.5-1.5) 1 (0.5-1.62) 0.31
SHS at baseline 0.12 0.01 0 (0-2) 0 (0-1) 0.01
DAS28 at 2-year 
follow up
0.06 0.16 2.91 (1.28)& 2.84 (1.26)& 0.78
HAQ at 2-year 
follow up
0.05 0.24 0.44 (0-1) 0.38 (0-0.88) 0.72
SHS at 2-year 
follow up
0.20 0.00 2 (0-9) 0 (0-3) 0.00
#Spearman correlation $Median with IQR unless stated otherwise&Mean with SD P-value of correlation2 P-value ACPA positive versus ACPA 
negative.
ACPA = anti-citrullinated protein antibody; DAS = disease activity score; HAQ = Health Assessment Questionnaire; IQR = interquartile range; 
SD = standard deviation; SHS = Sharp-van der Heijde score.Ursum et al. Arthritis Research & Therapy 2010, 12:R8
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found with SHS (r = -0.04, P = 0.54). When correcting for
baseline DAS or baseline HAQ, these correlations were
no longer present.
In the subgroup of patients with a positive IgM-RF sta-
tus at baseline there was no correlation between IgM-RF
levels and SHS (r = 0.05, P = 0.38).
Change in autoantibody levels and outcome
First-year change in levels and outcome at two year follow-up
Absolute or relative changes in ACPA level in the first
year were not correlated to DAS28, HAQ or SHS at the
two-year follow up (all P  > 0.13; Figure 1). First-year
changes in IgM-RF level were not correlated to DAS28
and HAQ (Figure 1), but absolute and relative changes
were modestly correlated to SHS at two years (r = -0.17
vs. R = -0.15, both P < 0.001). In ACPA or IgM-RF-posi-
tive patients, absolute as well as relative changes in levels
in the first year were not correlated with the two-year
outcome measures (all P > 0.10). ACPA or IgM-RF-nega-
tive patients were not further analysed since their levels
did not change significantly.
Discussion
The well-known association between ACPA or RF status
and radiographic outcome was confirmed in the present
study. Therefore, we focussed on ACPA and IgM-RF lev-
els at baseline and changes in the year thereafter in rela-
tion to outcome at two years, to investigate whether this
would provide additional prognostic information in early
arthritis patients.
The results were that baseline levels were only margin-
ally associated with later radiographic damage. The first-
year change in IgM-RF levels was modestly associated
with SHS at the two-year follow up; however, this associa-
tion was lost in the subgroup of patients with a positive
baseline status.
It was also noted that ACP A and RF rarely switched
from negative to positive after one year: in 2 and 3%,
respectively. On the other hand, decreases in levels over
the first year occurred in the majority of patients, with a
median decrease in level of 22% for ACPA and 28% for
RF. Recently, another study in very early RA patients
r e p o r t e d  a n  i n c r e a s e  o f  A C P A  l e v e l s  o f  1 0 %  a n d  a
decrease of IgM-RF levels of 14% [30]. The marked
decrease found in the present study is probably due to
treatment, because it is similar to what has been found in
reaction to TNF-blocking therapy in established RA [31].
The differential decrease supports the notion that RF is
more a disease activity marker and ACPA more a disease-
specific marker [31,32].
Table 2: The relation between IgM-RF status and levels and outcome variables
Correlation of 
IgM-RF levels at 
baseline#
P1 IgM-RF positive at
baseline (n = 255)$
IgM-RF negative at
baseline (n = 280)$
P2
IgM-RF level at 
baseline (IU/ml), 
median (IQR)
x 100 (60-200) 10 (6-14)
IgM-RF level at 1 
year (IU/ml), 
median (IQR)
x 51 (23-97) 9 (5-10)
DAS28 at baseline 0.11 0.01 4.88 (1.19) 1.66 (1.29) 0.01
HAQ at baseline 0.01 0.79 1 (0.5-1) 0.94 (0.5-1.5) 0.49
SHS at baseline 0.11 0.02 0 (0-1) 0 (0-0) 0.00
DAS28 at 2-year 
follow-up
0.17 0.69 2.92 (1.30)& 2.84 (1.23)& 0.58
HAQ at 2-year 
follow-up
0.04 0.41 0.5 (0-0.88) 0.38 (0-0.88) 0.43
SHS at 2-year 
follow-up
0.22 0.00 2 (0-9) 0 (0-4) 0.00
#Spearman correlation $Median with IQR unless stated otherwise&Mean with SD P-value of correlation2 P-value IgM-RF positive versus IgM-
RF negative.
DAS = disease activity score; HAQ = Health Assessment Questionnaire; Ig = immunoglobulin; IQR = interquartile range; RF = rheumatoid 
factor; SD = standard deviation; SHS = Sharp-van der Heijde score.Ursum et al. Arthritis Research & Therapy 2010, 12:R8
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Absolute change of IgM-RF and ACPA compared with the absolute change of DAS28, HAQ and SHS
Figure 1 Absolute change of IgM-RF and ACPA compared with the absolute change of DAS28, HAQ and SHS. The x-axes of a, c and f represent 
change in anti-citrullinated protein antibody (ACPA) levels in the first year. The x-axes of b, d and e represent the change in IgM-rheumatoid factor 
(RF) levels in the first year. Negative numbers indicate a decrease in levels whereas a positive number indicates an increase in levels. The Y-axes of a 
and b represent the change in the Disease Activity Score on 28 joints (DAS28) in the first year. The Y-axes of c and d represent the change in the Health 
Assessment Score (HAQ) in the first year. The Y-axes of e and f represent the change in the Sharp/van der Heijde Score (SHS) in the first year. Negative 
numbers indicate a decrease in the score and a positive number an increase, though for the SHS only an increase in score is possible.Ursum et al. Arthritis Research & Therapy 2010, 12:R8
http://arthritis-research.com/content/12/1/R8
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At baseline, ACPA levels and status were associated
only with SHS at baseline, while IgM-RF levels and status
were associated with DAS28 and SHS at baseline, as was
also reported previously [20,30]. For the two-year out-
come, there was only a correlation between baseline
autoantibody levels and SHS, as had been found before
[18,20,24,30], although most studies [3,8,10-15] only
addressed autoantibody status. High autoantibody levels
at baseline seem to be modestly associated with future
radiographic damage. However, in the present study these
associations were lost when stratifying for autoantibody
status. Previous studies did not analyse separately accord-
ing to autoantibody status. Therefore, their results could
be a reflection of autoantibody status.
The present results show that changes in ACPA level
during the first year of follow up are not correlated to the
outcome at two years, while there was a weak but nega-
tive correlation in the first-year change in IgM-RF levels
and SHS at two years. One earlier study reported the
absence of a relation between changes in antibody levels
and changes in disease activity in the same time period
[2]. We are not aware of any study reporting changes in
levels as a predictor for outcome later in the disease
course.
Conclusions
In conclusion, measurement of ACPA or RF levels in the
first year in early arthritis patients does not provide addi-
tional information over autoantibody status at baseline in
the prediction of the outcome after two years. As sero-
conversion of autoantibody status after one year is rare,
except for downward seroconversion of IgM-RF , it does
not seem useful in general to repeat these tests. It is more
the presence than the levels of the autoantibodies that
counts.
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